0000899243-21-035130.txt : 20210903 0000899243-21-035130.hdr.sgml : 20210903 20210903163111 ACCESSION NUMBER: 0000899243-21-035130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210901 FILED AS OF DATE: 20210903 DATE AS OF CHANGE: 20210903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HOLMLUND JON T CENTRAL INDEX KEY: 0001227367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39114 FILM NUMBER: 211236950 BUSINESS ADDRESS: STREET 1: 2292 FARADAY AVE CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 7609319200 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galera Therapeutics, Inc. CENTRAL INDEX KEY: 0001563577 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461454898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 WEST LIBERTY BLVD #100 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-725-1500 MAIL ADDRESS: STREET 1: 2 WEST LIBERTY BLVD #100 CITY: MALVERN STATE: PA ZIP: 19355 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-01 0 0001563577 Galera Therapeutics, Inc. GRTX 0001227367 HOLMLUND JON T C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD #100 MALVERN PA 19355 0 1 0 0 Chief Medical Officer Common Stock 2021-09-01 4 M 0 47756 2.43 A 47756 D Common Stock 2021-09-01 4 S 0 47756 8.4701 D 0 D Stock Option 2.43 2021-09-01 4 M 0 47756 0.00 D 2026-03-31 Common Stock 47756 61142 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2019. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.11 to $9.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option has fully vested and is currently exercisable. /s/ Christopher Degnan, Attorney-in-Fact for Jon T. Holmlund 2021-09-03